Drugs / JNJ-55375515
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03405441 | Jan → Sep 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02623491 | Nov 2015 → Sep 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-55375515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03405441 ↗ |
| Route | Oral | “after administration of single and multiple oral doses” NCT02623491 ↗ |